The move marks a turning point in 23andMe’s tumultuous decline. Founded in 2006 by Wojcicki, the company initially gained traction with its saliva-based ancestry kits and went public in 2021. By the ...

Me is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, ...

After a brief court dispute, 23andMe and all its assets are up for auction once again. The second time around, former CEO Amy ...

Bankrupt genetic testing firm 23andMe is seeking to reopen bidding on its assets, including over 15 million customer DNA ...

Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...

It's only a matter of time before cybercriminals begin to use artificial intelligence-enabled tools, open-source software and ...

Regeneron acquires 23andMe's genetics services for (Dollar) 256 million * Customer privacy safeguards will remain in place under a court-monitored //process * Lemonaid Health excluded from the deal ...

Regeneron will acquire 23andMe’s core assets for $256 million, ensuring customer data privacy and continuing the mission of accessible, genome-based health insights.

Regeneron Pharmaceuticals has announced plans to acquire the genetic testing company 23andMe for $256 million, with a clear ...

Amy Klobuchar are rolling out a bipartisan measure to protect sensitive genetic data in response to privacy concerns sparked by 23andMe's bankruptcy, Fox News Digital has learned. Cornyn ...

23andMe's sale to Regeneron transfers genetic data for drug development, raising privacy issues and concerns over consumer control and benefits. Genetic information submitted by millions of ...

Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million following its bankruptcy filing due to declining demand and a significant data breach in 2023. The acquisition excludes ...